Antiemetic Prescription Fills in Pregnancy: A Drug Utilization Study Among 762,437 Pregnancies in Norway

References

• Einarson TR, Piwko C, Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J Popul Ther Clin Pharmacol. 2013;20(2):e171–e183.23863575
   PubMedGoogle Scholar
• Gazmararian JA, Petersen R, Jamieson DJ, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol. 2002;100(1):94–100. doi:10.1016/s0029-7844(02)02024-012100809
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin No. 189: nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15–e30. doi:10.1097/AOG.000000000000245629266076
   PubMedGoogle Scholar
• Veenendaal MVE, van Abeelen AFM, Painter RC, van der Post JAM, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011;118(11):1302–1313. doi:10.1111/j.1471-0528.2011.03023.x21749625
   PubMed Web of Science ®Google Scholar
• Heitmann K, Nordeng H, Havnen GC, Solheimsnes A, Holst L. The burden of nausea and vomiting during pregnancy: severe impacts on quality of life, daily life functioning and willingness to become pregnant again - results from a cross-sectional study. BMC Pregnancy Childbirth. 2017;17(1):75. doi:10.1186/s12884-017-1249-028241811
   PubMed Web of Science ®Google Scholar
• Tan A, Lowe S, Henry A. Nausea and vomiting of pregnancy: effects on quality of life and day-to-day function. Aust N Z J Obstet Gynaecol. 2018;58(3):278–290. doi:10.1111/ajo.1271428949009
   PubMed Web of Science ®Google Scholar
• Tsakiridis I, Mamopoulos A, Athanasiadis A, Dagklis T. The management of nausea and vomiting of pregnancy: synthesis of national guidelines. Obstet Gynecol Surv. 2019;74(3):161–169. doi:10.1097/OGX.000000000000065431634919
   PubMed Web of Science ®Google Scholar
• Campbell K, Rowe H, Azzam H, Lane CA. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can. 2016;38(12):1127–1137. doi:10.1016/j.jogc.2016.08.00927986189
   PubMedGoogle Scholar
• Royal College of Obstetricians & Gynaecologists. The management of nausea and vomiting of pregnancy and hyperemesis gravidarum. Green-top guidelines no 69; 2016. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg69-hyperemesis.pdf. Accessed 1221, 2020.
   Google Scholar
• Fiaschi L, Nelson-Piercy C, Deb S, King R, Tata LJ. Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study. BJOG. 2019;126(10):1201–1211. doi:10.1111/1471-0528.1566230786126
   PubMed Web of Science ®Google Scholar
• Taylor LG, Bird ST, Sahin L, et al. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Pharmacoepidemiol Drug Saf. 2017;26(5):592–596. doi:10.1002/pds.418528220993
   PubMed Web of Science ®Google Scholar
• Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2018;31(18):2492–2505. doi:10.1080/14767058.2017.134280528614956
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2017.
   Google Scholar
• The Norwegian Society of Obstetrics and Gynecology. Veileder i fødselshjelp [Obstetric guidelines issued by the Norwegian Society of Obstetrics and Gynaecology]; 2014. Available from: https://www.legeforeningen.no/foreningsledd/fagmed/norsk-gynekologisk-forening/veiledere/veileder-i-fodselshjelp-2014/7.-emesis-og-hyperemesis-gravidarum/. Accessed 1221, 2020. Norwegian.
   Google Scholar
• Quinlan JD Nausea and vomiting in pregnancy. BMJ Best Practice. 2020. Available from: https://bestpractice.bmj.com/topics/en-gb/999. Accessed 1221, 2020.
   Google Scholar
• Schaefer C, Peters PWJ, Miller RK. Drugs During Pregnancy and Lactation. 3rd ed. London: Academic Press; 2015.
   Google Scholar
• Smith JA, Fox KA, Clark SM Nausea and vomiting of pregnancy: treatment and outcome. UpToDate 2020.
   Google Scholar
• European Medicines Agency. PRAC recommendations on signals; 2019. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf. Accessed 1221, 2020.
   Google Scholar
• Huybrechts KF, Hernández-Díaz S, Straub L, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA. 2018;320(23):2429–2437. doi:10.1001/jama.2018.1830730561479
   PubMed Web of Science ®Google Scholar
• Lemon LS, Bodnar LM, Garrard W, et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J Epidemiol. 2020;49(2):648–656. doi:10.1093/ije/dyz25531860078
   PubMed Web of Science ®Google Scholar
• Parker SE, Van Bennekom C, Anderka M, Mitchell AA. National birth defects prevention study. Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects. Obstet Gynecol. 2018;132(2):385–394. doi:10.1097/AOG.000000000000267929995744
   PubMed Web of Science ®Google Scholar
• Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol. 2019;83:14–20. doi:10.1016/j.reprotox.2018.10.01030385129
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Hernández-Díaz S, Bateman BT. Contextualizing potential risks of medications in pregnancy for the newborn-the case of ondansetron. JAMA Pediatr. 2020;174(8):747–748. doi:10.1001/jamapediatrics.2020.132532478805
   PubMed Web of Science ®Google Scholar
• Damkier P, Kaplan YC, Shechtman S, et al. Ondansetron should never be used in pregnancy: against: ondansetron in pregnancy revisited. BJOG. 2021;128(1):111–112. doi:10.1111/1471-0528.1647632991063
   PubMed Web of Science ®Google Scholar
• Irgens LM. The medical birth registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435–439.10857866
   PubMed Web of Science ®Google Scholar
• Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. Nor Epidemiol. 2008;18(2):129–136.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2021; 2020. Available from: https://www.whocc.no/atc_ddd_index/. Accessed 1221, 2020.
   Google Scholar
• Elseviers M, Wettermark B, Almarsdóttir AB, et al. Drug Utilization Research: Methods and Applications. Toronto: Wiley-Blackwell; 2016.
   Google Scholar
• Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;122(5):957–965. doi:10.1097/AOG.0b013e3182a603bb24104771
   PubMed Web of Science ®Google Scholar
• Havnen GC, Truong MB, Do MH, Heitmann K, Holst L, Nordeng H. Women’s perspectives on the management and consequences of hyperemesis gravidarum - a descriptive interview study. Scand J Prim Health Care. 2019;37(1):30–40. doi:10.1080/02813432.2019.156942430822254
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009;338(jun18 1):b2255. doi:10.1136/bmj.b225519541696
   PubMed Web of Science ®Google Scholar
• Heitmann K, Holst L, Lupattelli A, Maltepe C, Nordeng H. Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers. BMC Pregnancy Childbirth. 2015;15(1):321. doi:10.1186/s12884-015-0746-226628289
   PubMed Web of Science ®Google Scholar
• Van den Heuvel JM, Farzan N, van Hoek M, Maitland-van der Zee AH, Ahmadizar F. Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands. BMJ Open Diabetes Res Care. 2020;8(1):e000767. doi:10.1136/bmjdrc-2019-000767
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: metoclopramide only containing medicinal products; 2013. Available from: https://www.ema.europa.eu/en/documents/referral/assessment-report-metoclopramide-containing-medicines_en.pdf. Accessed 1221, 2020.
   Google Scholar
• Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HEK, De Jong-van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–568. doi:10.1111/j.1471-0528.2006.00927.x16637899
   PubMed Web of Science ®Google Scholar
• Demailly R, Escolano S, Quantin C, Tubert-Bitter P, Ahmed I. Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample. Pharmacoepidemiol Drug Saf. 2017;26(9):1126–1134. doi:10.1002/pds.426528758270
   PubMed Web of Science ®Google Scholar
• Bérard A, Sheehy O, Gorgui J, Zhao JP, Soares de Moura C, Bernatsky S. New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. J Clin Epidemiol. 2019;116:39–48. doi:10.1016/j.jclinepi.2019.07.01431352006
   PubMed Web of Science ®Google Scholar
• Schrager NL, Adrien N, Werler MM, Parker SE, Van Bennekom C, Mitchell AA. Trends in first-trimester nausea and vomiting of pregnancy and use of select treatments: findings from the national birth defects prevention study. Paediatr Perinat Epidemiol. 2021;35(1):57–64. doi:10.1111/ppe.12705
   Web of Science ®Google Scholar
• Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int. 2013;2013:909860. doi:10.1155/2013/90986024396830
   PubMed Web of Science ®Google Scholar
• Fiaschi L, Nelson-Piercy C, Tata LJ. Hospital admission for hyperemesis gravidarum: a nationwide study of occurrence, reoccurrence and risk factors among 8.2 million pregnancies. Hum Reprod. 2016;31(8):1675–1684. doi:10.1093/humrep/dew12827251205
   PubMed Web of Science ®Google Scholar
• Fejzo MS, Macgibbon KW, Romero R, Goodwin TM, Mullin PM. Recurrence risk of hyperemesis gravidarum. J Midwifery Womens Health. 2011;56(2):132–136. doi:10.1111/j.1542-2011.2010.00019.x21429077
   PubMed Web of Science ®Google Scholar
• Trogstad LIS, Stoltenberg C, Magnus P, Skjærven R, Irgens LM. Recurrence risk in hyperemesis gravidarum. BJOG. 2005;112(12):1641–1645. doi:10.1111/j.1471-0528.2005.00765.x16305568
   PubMed Web of Science ®Google Scholar
• Fejzo MS, Ingles SA, Wilson M, et al. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):13–17. doi:10.1016/j.ejogrb.2008.07.00318752885
   PubMed Web of Science ®Google Scholar
• Fejzo MS, Myhre R, Colodro-Conde L, et al. Genetic analysis of hyperemesis gravidarum reveals association with intracellular calcium release channel (RYR2). Mol Cell Endocrinol. 2017;439:308–316. doi:10.1016/j.mce.2016.09.01727663074
   PubMed Web of Science ®Google Scholar
• Fejzo MS, Sazonova OV, Sathirapongsasuti JF, et al. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun. 2018;9(1):1178. doi:10.1038/s41467-018-03258-029563502
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cantor RM, MacGibbon K, et al. Familial aggregation of hyperemesis gravidarum. Am J Obstet Gynecol. 2011;204(3):230.e1–230.e7. doi:10.1016/j.ajog.2010.09.018
   Web of Science ®Google Scholar
• Kjeldgaard HK, Eberhard-Gran M, Benth JS, Nordeng H, Vikanes ÅV. History of depression and risk of hyperemesis gravidarum: a population-based cohort study. Arch Womens Ment Health. 2017;20(3):397–404. doi:10.1007/s00737-016-0713-628064341
   PubMed Web of Science ®Google Scholar
• Whitehead SA, Andrews PLR, Chamberlain GVP. Characterisation of nausea and vomiting in early pregnancy: a survey of 1000 women. J Obstet Gynaecol. 1992;12(6):364–369. doi:10.3109/01443619209025932
   Google Scholar
• Heitmann K, Solheimsnes A, Havnen GC, Nordeng H, Holst L. Treatment of nausea and vomiting during pregnancy - a cross-sectional study among 712 Norwegian women. Eur J Clin Pharmacol. 2016;72(5):593–604. doi:10.1007/s00228-016-2012-626815908
   PubMed Web of Science ®Google Scholar
• Chortatos A, Haugen M, Iversen PO, Vikanes Å, Magnus P, Veierød MB. Nausea and vomiting in pregnancy: associations with maternal gestational diet and lifestyle factors in the Norwegian mother and child cohort study. BJOG. 2013;120(13):1642–1653. doi:10.1111/1471-0528.1240623962347
   PubMed Web of Science ®Google Scholar
• Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A. Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002;186(5):S228–S231. doi:10.1067/mob.2002.12305412011891
   PubMed Web of Science ®Google Scholar
• Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2008;198(1):71.e1–71.e7. doi:10.1016/j.ajog.2007.05.051
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Evidence review: doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy; 2019. Available from: https://www.nice.org.uk/advice/es20/evidence/evidence-review-pdf-6836042269. Accessed 1221, 2020.
   Google Scholar
• Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S. Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep. 2017;4(2):106–116. doi:10.1007/s40471-017-0104-129399433
   PubMedGoogle Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment; 2020. Available from: https://www.whocc.no/filearchive/publications/2021_guidelines_web.pdf. Accessed 1221, 2020.
   Google Scholar